China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth

News provided by

Mar 26, 2013, 01:37 ET

NEW YORK, March 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth
http://www.reportlinker.com/p01154051/China-Pharmaceutical-Market-Outlook---Government-Incentives-Healthcare-Reform-and-a-Rapidly-Ageing-Population-Provide-Strong-Stimulus-for-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care

Summary

GBI Research's new report: "China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth" provides in-depth analysis of the trends, issues and challenges facing the Chinese pharmaceutical market. It details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie. It includes information on the regulatory guidelines for the manufacture, development and distribution of pharmaceuticals. The report also covers information on the competitive landscape in the Chinese pharmaceutical market, identifying market leaders and key trends in investment. It also includes the key drivers and barriers of the pharmaceutical market in more detail. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

China is currently one of the most important markets in the pharmaceutical industry. It is the most populous country in the world, with a recorded population of over 1.34 billion as of 2011. The country has the second-largest economy after the US with a GDP of $7.3 trillion as of 2011, and its economy is one of the fastest growing in the world, with average growth of 10.6% over the last decade (World Bank, 2012). China is the world's largest exporter and second-largest importer of goods.

In 2011, China overtook Germany to become the third largest pharmaceutical market in the world, and is predicted to overtake Japan by 2015 to become the second largest. In 2011, its estimated value was approximately $64 billion. The size of China's pharmaceutical market is primarily a result of its large population rather than its maturity, as it is still an emerging market. The Chinese pharmaceutical market has the world's largest manufacturing capabilities, producing more than 4,500 drugs and exporting various pharmaceutical products such as acetylsalicylic acid and metamizole to the global market. Recent healthcare reforms have been driving the pharmaceutical market by increasing public access to drugs. In addition, recent population changes such as a majority move from rural to urban China, a rapidly aging community and an increasing overweight population are driving the value of the Chinese pharmaceutical market.

Scope

The report analyzes the Chinese pharmaceutical market, looking at -
- Macroeconomic analysis of China covering economic, demographic and market-specific indicators
- Market analysis of segments such as branded and generic drugs, prescribed and OTC drugs, and biopharmaceuticals
- Industry landscape, looking at pharmaceutical pricing policies, supply chain, drug regulations and healthcare reforms
- Competitive profiling of major domestic and international companies operating in the Chinese pharmaceutical market in addition to the important M&A deals in recent years
- Drivers and barriers of the Chinese pharmaceutical market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong growth
- Devise a more tailored country strategy through understanding key drivers of and barriers to the pharmaceutical market
- Develop key strategic initiatives by understanding leading companies' key focus areas
- Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 China Pharmaceutical Market Outlook – Introduction 8
3 China Pharmaceutical Market Outlook – Macroeconomic Analysis 9
3.1 General Economics 9
3.1.1 Gross Domestic Product 9
3.1.2 Inflation 11
3.1.3 Exchange Rate 12
3.1.4 Trade Balance 13
3.1.5 Foreign Direct Investment 17
3.2 Demographic 18
3.2.1 Population Size 18
3.2.2 Population Distribution 20
3.3 Health and Healthcare 22
3.3.1 Healthcare Expenditure 22
3.3.2 Public and Private Expenditure 25
3.3.3 Healthcare Facilities 27
3.3.4 Immunization 29
3.3.5 Smoking and Alcohol Use Prevalence 30
3.3.6 Obesity 32
3.3.7 Life Expectancy 33
3.3.8 Leading Causes of Death 34
4 China Pharmaceutical Market Outlook – Market Segments 35
4.1 Branded and Generic Drugs 35
4.2 Over-the-Counter and Prescription Drugs 39
4.3 Biopharmaceuticals 42
5 China Pharmaceutical Market Outlook – Industry Characteristics 44
5.1 Pricing Policy 44
5.2 Regulatory Landscape 45
5.2.1 Drug Manufacturing Regulations 46
5.2.2 New Drug Approval 46
5.2.3 Intellectual Property Protection 47
5.2.4 Advertising 47
5.3 Healthcare Overview 48
5.3.1 Healthcare Reform 48
5.3.2 Insurance and Reimbursement 49
5.4 Pharmaceutical Supply Chain 50
6 China Pharmaceutical Market Outlook – Competitive Landscape 51
6.1 Domestic Companies in China 51
6.1.1 Sinopharm 51
6.1.2 Shanghai Pharmaceutical 52
6.1.3 Jointown Pharmaceutical 52
6.1.4 Nanjing Pharmaceutical 53
6.1.5 Harbin Pharmaceutical 53
6.2 Macroscopic Domestic Deals Overview 54
6.3 Foreign Companies in China 56
7 China Pharmaceutical Market Outlook – Market Drivers and Barriers 57
7.1 Drivers 57
7.1.1 Increasing Overweight and Obese Population 57
7.1.2 High Smoking Prevalence 57
7.1.3 Aging Population 58
7.1.4 Government Financial Support 58
7.1.5 Healthcare Reforms 58
7.1.6 Increasing Urbanization 59
7.2 Barriers 59
7.2.1 Poor Drug Quality 59
7.2.2 Competition from Neighboring Countries 59
7.2.3 Popularity of TCM 59
7.2.4 Increasing Labor Costs 60
7.2.5 Poor Intellectual Property Protection 60
8 China Pharmaceutical Market Outlook – Appendix 61
8.1 Market Definitions 61
8.2 Abbreviations 61
8.3 Bibliography 62
8.4 Research Methodology 64
8.4.1 Coverage 64
8.4.2 Secondary Research 64
8.4.3 Primary Research 64
8.4.4 Expert Panel Validation 65
8.5 Contact Us 65
8.6 Disclaimer 65

List of Tables

Table 1: Leading Causes of Death, China, Deaths per 100,000, 2009 34
Table 2: Branded and Generic Drugs, China, Branded/Generic Price Ratio, 2009 37
Table 3: OTC Pharmaceuticals, China, Top OTC Product per Class, 2010 41
Table 4: OTC Pharmaceuticals, China, Top 10 OTC Pharmaceutical Manufacturers, 2010 41
Table 5: Top Multinational Companies, China, Sales ($m) and Share of the Multinational Market (%), 2011 56

List of Figures

Figure 1: Gross Domestic Product, China, Value ($bn) and Annual Growth (%), 2005–2017 9
Figure 2: Gross Domestic Product per Capita ($), China, 2005–2017 10
Figure 3: Consumer Price Index, China, 2005–2017 11
Figure 4: Consumer Price, China, Annual Price Change (%), 2005–2017 11
Figure 5: Exchange Rate (USD/CNY), China, 2005–2012 12
Figure 6: Import of Goods and Services, China, Value ($bn) and Annual Growth (%), 2005–2017 13
Figure 7: Import of Goods, China, Value ($bn) and Annual Growth (%), 2005–2017 13
Figure 8: Import of Goods and Services Comparison, China, Value ($bn), 2005–2017 14
Figure 9: Export of Goods and Services, China, Value ($bn) and Annual Growth (%), 2005–2017 14
Figure 10: Export of Goods, China, Value ($bn) and Annual Growth (%), 2005–2017 15
Figure 11: Export of Goods and Services Comparison, China, Value ($bn), 2005–2017 16
Figure 12: Trade Balance, China, Value ($bn), 2005–2017 16
Figure 13: Foreign Direct Investment, China, Net Investment ($bn), 2005–2011 17
Figure 14: Population Size, Three Most Populous Countries, Population (billion), 2005–2017 18
Figure 15: Annual Population Growth, China, Percentage (%), 2005–2017 18
Figure 16: Crude Birth and Death Rates, China, Rate (Per 1,000 People), 2005–2012 19
Figure 17: Population Distribution by Age, China, Percentage (%), 2000–2020 20
Figure 18: Population Distribution by Gender, China, Percentage (%), 2011 20
Figure 19: Population Distribution by Region, China, Percentage (%), 2005–2015 21
Figure 20: Population Size by Region, China, Population (million), 2005–2017 21
Figure 21: Healthcare Expenditure (% of GDP), Global, 2010 22
Figure 22: Healthcare Expenditure (% of GDP and $bn), China, 2005–2011 23
Figure 23: Healthcare Expenditure per Capita ($), China, 2005–2011 23
Figure 24: Healthcare Expenditure, China, Rural and Urban Distribution (%), 2009 24
Figure 25: Public and Private Healthcare Expenditure, China, Percentage of Total Healthcare Expenditure (%), 2005–2011 25
Figure 26: Government Healthcare Expenditure, China, Percentage of Government Expenditure (%), 2005–2011 26
Figure 27: Out-of-Pocket Healthcare Expenditure, China, Percentage of Private Healthcare Expenditure (%), 2005–2011 26
Figure 28: Healthcare Organizations, China, Distribution (%), 2009 27
Figure 29: Urban and Rural Hospitals, China, Distribution (%), 2009 27
Figure 30: Hospital Bed Availability, China, Hospital Beds per 1,000 People, 2002–2011 28
Figure 31: Physician Availability, China, Physicians per 1,000 People, 2002–2011 28
Figure 32: Children Immunized against DPT and Measles, China, Percentage (%), 2002–2011 29
Figure 33: Smoking Prevalence, China, Percentage of Population (%), 2009–2010 30
Figure 34: Alcohol Use Prevalence, China, Percentage of Population (%), 2010 31
Figure 35: Alcohol Use Prevalence, China, Total Pure Alcohol Consumption (billion liters), 2007–2017 31
Figure 36: Overweight Population, China, Proportion of Population (%), 2005–2015 32
Figure 37: Life Expectancy (Years), China, 2005–2017 33
Figure 38: Branded and Generic Drugs, China, Market Share by Hospital, 2010 35
Figure 39: Branded and Generic Drugs, China, Revenue Market Share by Therapeutic Category (%), 2010 36
Figure 40: Branded and Generic Drugs, China, Sales Quantity Market Share by Therapeutic Category (%), 2010 36
Figure 41: Generic Drugs, China, Breakdown by Therapeutic Category (%), 2008 38
Figure 42: Pharmaceutical Market, China, Breakdown by Market Segment (%), 2009 39
Figure 43: OTC Market, China, Breakdown by Product Type (%), 2011 40
Figure 44: Biopharmaceuticals Market, China, Breakdown of Product Types by Sales (%), 2010 42
Figure 45: Domestic Deals, China, Types of Deals, 2007–2012 54